Bicycle Therapeutics (50BA) Stock Statistics & Valuation Metrics

Bicycle Therapeutics has a market cap or net worth of EUR 225.14M. The enterprise value is -EUR 197.73M.

Market Cap

EUR 225.14M

Enterprise Value

-EUR 197.73M

Bicycle Therapeutics has 50,655,815 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

50,655,815

Owned by Insiders

22.92%

Owned by Institutions

7.93%

Bicycle Therapeutics’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -37.34%.

Return on Equity (ROE)

-0.36

Return on Assets (ROA)

-0.31

Return on Invested Capital (ROIC)

-37.34%

Return on Capital Employed (ROCE)

-0.37

Revenue Per Employee

252.03K

Profits Per Employee

-760.28K

Employee Count

288

Asset Turnover

0.10

Inventory Turnover

0.00

The current PE Ratio of Bicycle Therapeutics is -1.86. Bicycle Therapeutics’s PEG ratio is -0.03.

PE Ratio

-1.86

PS Ratio

3.16

PB Ratio

0.52

Price to FCF

-1.50

Price to Operating Cash Flow

-1.51

PEG Ratio

-0.03

In the last 12 months, Bicycle Therapeutics had revenue of 72.59M and earned -218.96M in profits. Earnings per share was -3.16.

Revenue

72.59M

Gross Profit

72.59M

Operating Income

-247.72M

Pretax Income

-218.81M

Net Income

-218.96M

EBITDA

-212.18M

Earnings Per Share (EPS)

-3.16

In the last 12 months, operating cash flow was -174.85M and capital expenditures -1.86M, giving a free cash flow of -176.70M billion.

Operating Cash Flow

-174.85M

Free Cash Flow

-176.70M

Free Cash Flow per Share

-2.53

Bicycle Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-66.78%

Earnings Yield

-53.67%

Beta

1.29

52-Week Price Change

-41.89%

50-Day Moving Average

3.24

200-Day Moving Average

3.72

Relative Strength Index (RSI)

45.22

Average Volume (3m)

775

Bicycle Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Mar 02, 2027

Ex-Dividend Date

―

Bicycle Therapeutics as a current ratio of 11.98, with Debt / Equity ratio of 2.87%

Current Ratio

11.98

Quick Ratio

11.98

Debt to Market Cap

0.01

Net Debt to EBITDA

2.88

Interest Coverage Ratio

-1202.51

In the past 12 months, Bicycle Therapeutics has paid 152.00K in taxes.

Income Tax

152.00K

Effective Tax Rate

-0.00

Bicycle Therapeutics EV to EBITDA ratio is 1.42, with an EV/FCF ratio of 1.08.

EV to Sales

-2.29

EV to EBITDA

1.42

EV to Free Cash Flow

1.08

EV to Operating Cash Flow

1.09

Bicycle Therapeutics has EUR 469.93M in cash and marketable securities with EUR 14.18M in debt, giving a net cash position of EUR 455.74M billion.

Cash & Marketable Securities

EUR 469.93M

Total Debt

EUR 14.18M

Net Cash

EUR 455.74M

Net Cash Per Share

EUR 9.00

Tangible Book Value Per Share

EUR 7.22

Gross margin is 100.00%, with operating margin of -189.50%, and net profit margin of -169.75%.

Gross Margin

100.00%

Operating Margin

-189.50%

Pretax Margin

-166.52%

Net Profit Margin

-169.75%

EBITDA Margin

-160.78%

EBIT Margin

-166.29%

The average price target for Bicycle Therapeutics is EUR 4.46, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target

EUR 4.46

Price Target Upside

44.81% Upside

Analyst Consensus

Neutral

Analyst Count

2

Revenue Growth Forecast

181.95%

EPS Growth Forecast

46.67%

Smart Score

4

AI Score

―